Skip to search formSkip to main contentSkip to account menu

Glipizide 10 MG Oral Tablet

Known as: GLIPIZIDE 10MG TAB [VA Product], GLIPIZIDE 10MG TAB, GLIPIZIDE 10MG TAB,UD [VA Product] 
National Institutes of Health

Related topics

Related topics

20 relations
24 HR Glipizide 10 MG Extended Release Oral TabletCroscarmellose SodiumDiabetes Mellitus, Insulin-DependentDiabetes Mellitus, Non-Insulin-Dependent

Narrower (1)

Glipizide 10 MG Oral Tablet [Glucotrol]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes
Evaluation of effects of glipizide gastrointestinal therapeutic system (GITS) administered once daily (AM or PM) and… 
2004
2004
Evaluation of the Efficacy and Safety of Once Daily Injection of Glargine Combined with Glipizide GITS in the Treatment of Type 2 Diabetes Mellitus
Objective To compare the blood glucose level and associated hypoglycemia risks by using insulin Glargine or human NPH both… 
2002
2002
A ‘Real-World’ Analysis of Persistence on and Adherence to Glipizide GITS, Glipizide IR and Glibenclamide in Managed Care among Patients with Type 2 Diabetes Mellitus
ObjectiveThis study compared persistence on and adherence to therapy with glipizide gastrointestinal therapeutic system (GITS… 
Highly Cited
2002
Highly Cited
2002
Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.
OBJECTIVE Epidemiological studies have implicated increased plasminogen-activated inhibitor 1 (PAI-1) as a marker or predictor of… 
2002
2002
Pharmacokinetics and Pharmacodynamics of Extended‐Release Glipizide GITS Compared with Immediate‐Release Glipizide in Patients with Type II Diabetes Mellitus
This study was designed to compare the pharmacokinetic and short‐term pharmacodynamic profile of extended‐release glipizide GITS… 
2002
2002
Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans.
The entrapment and retention of plasma low-density lipoproteins (LDL) by arterial proteoglycans (PG) is a process central to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)